Comments
Zydus Cadila on Thursday said it has received the final approval from the USFDA to market Sirolimus tablets (0.5 mg) with 180-days of marketing exclusivity.
As per IMS data in 2013, the sales of Sirolimus 0.5 mg was estimated at $11.7 million and the total market for Sirolimus was approximately $203.8 million, the Ahmedabad-based company said in a statement here.
The Group also received approval for Duloxetine delayed release capsules in strengths of 20, 30 and 60 mg. The sales for Duloxetine was estimated at $5.5 billion in 2013.
While Sirolimus tablets are immunosuppressant drugs used to prevent rejection in organ transplantation, Duloxetine delayed release capsules fall in the anti-depressants segment.
The Zydus Group now has 86 approvals and has so far filed 216 ANDAs since the commencement of filing process in FY 2003-04.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.